Search

Your search keyword '"Nakagama, Yu"' showing total 204 results

Search Constraints

Start Over You searched for: Author "Nakagama, Yu" Remove constraint Author: "Nakagama, Yu"
204 results on '"Nakagama, Yu"'

Search Results

2. Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

3. Malaria infection among adults residing in a highly endemic region from the Democratic Republic of the Congo

5. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

7. Differential cardiomyocyte transcriptomic remodeling during in vitro Trypanosoma cruzi infection using laboratory strains provides implications on pathogenic host responses

8. The landscape of drug resistance in Plasmodium falciparum malaria in the Democratic Republic of Congo: a mapping systematic review

9. Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities

10. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

14. Successful treatment of fulminant and recurrent lymphocytic myocarditis with calcineurin inhibitors.

17. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020

19. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome—Case series research

24. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome—Case series research.

26. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome

27. Malaria infection among adults residing in a highly endemic region from the Democratic Republic of the Congo

28. Cardiomyocyte transcriptomic signatures in response toTrypanosoma cruziinfection underpin Chagas cardiomyopathy progression

30. Usefulness of seasonal malaria chemoprevention in the Sahel

31. Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M

32. Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation

35. Antibody Responses after Bnt162b2 Vaccination in Japanese Geriatric Intermediate Care Facilities

36. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity

37. WHF recommendations for the use of echocardiography in Chagas disease

38. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

39. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

40. Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America

42. Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants

43. Nitric oxide derived from cytoglobin-deficient hepatic stellate cells causes suppression of cytochrome c oxidase activity in hepatocytes

44. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan

46. Cloaking the ACE2 receptor with salivary cationic proteins inhibits SARS-CoV-2 entry

47. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.

49. Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19

50. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

Catalog

Books, media, physical & digital resources